What is Non-HDL-C?
Non-HDL-C (non-high-density lipoprotein cholesterol) is a simple laboratory calculation obtained by subtracting HDL cholesterol from total cholesterol (Total Cholesterol - HDL-C = Non-HDL-C), which measures all cholesterol carried by atherogenic (plaque-forming) lipoproteins in your blood. 1
What Non-HDL-C Actually Measures
Non-HDL-C captures the cholesterol content of all atherogenic apolipoprotein B-containing lipoproteins, including:
- LDL (low-density lipoprotein)
- VLDL (very low-density lipoprotein)
- IDL (intermediate-density lipoprotein)
- Remnant particles
- Lipoprotein(a) 1, 2
The key advantage: HDL cholesterol does NOT accumulate in artery walls and does NOT contribute to atherosclerosis, so excluding it gives you a more accurate picture of your actual cardiovascular risk. 1
Why Non-HDL-C Matters Clinically
Superior to LDL-C for Risk Prediction
Non-HDL-C is a better predictor of cardiovascular events and treatment benefit than LDL-C alone because it accounts for all atherogenic particles, not just LDL. 1 This superiority has been confirmed in:
- Large population studies (UK Biobank)
- Meta-analyses of 110 prospective cohort registries
- Multiple intervention trials 1
Practical Advantages
Non-HDL-C can be measured without fasting, unlike calculated LDL-C which becomes unreliable after eating. 1 Specifically:
- Non-HDL-C remains stable in non-fasting samples when triglycerides are <4.5 mmol/L
- LDL-C can drop by up to 10% after meals due to triglyceride enrichment 1
- No additional cost - it's automatically calculated from your standard lipid panel 1
When Non-HDL-C is Especially Important
You should preferentially use non-HDL-C over LDL-C when triglycerides are ≥1.5 mmol/L (≥133 mg/dL) 1 because:
- Above this triglyceride level, cholesterol in LDL particles gets replaced by triglyceride
- This creates more atherogenic small dense LDL particles
- Calculated LDL-C becomes an unreliable reflection of actual LDL particle number 1
The Friedewald formula for calculating LDL-C completely fails when triglycerides exceed 4.5 mmol/L (400 mg/dL), but non-HDL-C remains accurate. 2
Clinical Use as a Treatment Target
Current Guideline Recommendations
The 2021 Canadian Cardiovascular Society guidelines strongly urge routine use of either non-HDL-C or ApoB instead of LDL-C as the lipid level of interest in initial screening and as a treatment target in all patients with triglyceride levels >1.5 mmol/L. 1
Target Values
Non-HDL-C targets are set 0.8 mmol/L (30 mg/dL) higher than corresponding LDL-C targets to account for the normal VLDL-C contribution. 2, 3 For example:
- If your LDL-C target is <2.0 mmol/L (<77 mg/dL), your non-HDL-C target would be <2.8 mmol/L (<108 mg/dL)
- For very high-risk patients: non-HDL-C <3.4 mmol/L (<130 mg/dL) 4
Common Clinical Scenarios
Residual Risk Despite Low LDL-C
Patients who achieve LDL-C goals but not non-HDL-C goals have higher triglycerides, BMI, and diabetes burden - indicating significant residual cardiovascular risk. 5 This highlights why checking non-HDL-C matters even when LDL-C appears controlled.
Metabolic Syndrome and Diabetes
Non-HDL-C is particularly valuable in patients with:
These conditions feature atherogenic dyslipidemia with accumulation of triglyceride-rich remnant particles that non-HDL-C captures but LDL-C misses.
Key Pitfall to Avoid
Do not assume adequate cardiovascular risk management based solely on LDL-C levels, especially in patients with elevated triglycerides or metabolic syndrome. Always calculate and assess non-HDL-C, as it provides superior risk stratification and identifies residual risk that LDL-C alone will miss. 1, 4